Memasolv

Memantine Hydrochloride, the active ingredient in Memasolv, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adult patients. The medication modulates glutamatergic neurotransmission, helping to reduce excitotoxic neuronal damage that contributes to cognitive decline.

GNH USA supplies Memasolv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance across multiple global markets.

Memasolv, a NMDA receptor antagonist, is used in the management of Alzheimer’s disease and related cognitive disorders. - Moderate to severe Alzheimer’s disease: improves cognition, daily functioning, and overall clinical status in affected patients. - Mild to moderate Alzheimer’s disease (off‑label): may provide symptomatic benefit in early stages, though evidence is limited. - Dementia of Alzheimer’s type: helps to stabilize functional abilities and delay progression of cognitive decline.

Memasolv may be associated with a range of adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate cranial pain. - Constipation: reduced bowel movements or hard stools. - Fatigue: feeling unusually tired or lacking energy. Serious or Rare Side Effects: - Seizures: occurrence of convulsive episodes. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Cardiac arrhythmia: irregular heart rhythm that may require medical attention.

Before prescribing Memasolv, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - History of seizures: use with caution and monitor for neurologic events. - Concomitant NMDA antagonists: avoid combined use to prevent additive neurotoxicity. - Pregnancy and lactation: safety not established; prescribe only when benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Memasolv can interact with other medicines; awareness of significant interactions helps to minimize adverse outcomes. Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neurotoxic risk. - Ketamine: additive NMDA blockade can lead to excessive CNS depression. - Other NMDA receptor antagonists: concurrent use may amplify neuropsychiatric effects. Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish the cognitive benefits of memantine. - Central nervous system depressants: can enhance dizziness or sedation. - Diuretics: may raise plasma concentrations of memantine by reducing renal clearance.